Background
Phase III, open-label RCT. 5760 patients with HR+ HER2- early breast cancer, stages II–III (anatomic high-risk based on nodal status or tumor size). Designed to test CDK4/6 inhibition in an unselected early BC population.
Interventions and follow up
Arm A: Palbociclib 125mg days 1–21 of 28-day cycle × 2 years + standard endocrine therapy
Arm B: Standard endocrine therapy alone
Primary endpoint: Invasive disease-free survival (IDFS)
mFollow up: 31 month
Arm B: Standard endocrine therapy alone
Primary endpoint: Invasive disease-free survival (IDFS)
mFollow up: 31 month
Results
IDFS: HR 0.93, 95% CI 0.76–1.15, P=.51 — not significant
4-yr IDFS: 84.2% vs 84.5% (Arm A vs B)
4-yr IDFS: 84.2% vs 84.5% (Arm A vs B)
Adverse events
Hematologic: grade ≥3 neutropenia 61.3% vs 0.7%; no increase in febrile neutropenia
Constitutional: grade ≥3 fatigue 1.7%
Other: palbociclib dose reductions 34.4%; discontinuation 42.0% (largely toxicity or patient preference)
Constitutional: grade ≥3 fatigue 1.7%
Other: palbociclib dose reductions 34.4%; discontinuation 42.0% (largely toxicity or patient preference)
Conclusions
Palbociclib added to adjuvant endocrine therapy did not improve IDFS in HR+ HER2- early breast cancer. The trial was definitively negative, with overlapping IDFS curves and no subgroup showing benefit.
Key Limitations
Key Limitations: Unselected population (stages II–III) included many patients with lower relapse risk, potentially diluting any treatment effect. Notably high discontinuation rate (42%) in the palbociclib arm may have reduced adherence and statistical power. mFollowup of 31 months may be insufficient to detect DFS differences — longer follow-up analyses are ongoing. No Ki-67 stratification; subsets with high Ki-67 or ≥4 nodes not powered for subgroup analysis.
Clinical Context
PALLAS was negative, in contrast to monarchE (abemaciclib). Differences may reflect palbociclib's intermittent dosing (3/4 weeks), lower CDK4 selectivity, higher discontinuation rate, and potentially different patient populations. Palbociclib is not approved in the adjuvant early BC setting. The contrast between PALLAS and monarchE suggests CDK4/6 inhibitor class effects should not be assumed uniform across agents.
References